Home › NDC Lookup › Ingredients › Haloperidol › 27241-0264-01
⚪image loading
(from DailyMed)

Haloperidol .5 mg Tablet, 100-count — NDC 27241-264-01 (Billing 27241-0264-01) · Product 27241-264

by Ajanta Pharma USA Inc. · 100 TABLET in 1 BOTTLE (27241-264-01)

NDC 27241-264-01 (billing 27241-0264-01) is a package of 100 tablets of Haloperidol .5 mg Tablet from Ajanta Pharma USA Inc., marketed since Sep 2026 and currently FDA-listed. It is the main listing for product NDC 27241-264, its only package size.

NDC 27241-0264-01
🏷️ FDA NDC (as labeled) 27241-264-01 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 27241-264-01
Product NDC 27241-264
11-digit billing NDC 27241026401
Application # ANDA218210
SPL Set ID 3af25358-362b-4046-98c9-1c12eb623e02
Established class (EPC) Typical Antipsychotic
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-09-14
Route ORAL
Dosage form TABLET
Substance HALOPERIDOL
Quick answers for NDC 27241-264-01
  • 11-digit billing NDC: 27241026401
Why two NDCs? The FDA registers this code as 27241-264-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 27241-0264-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

📗 Our plain-language guide HelloPharmacist
  • It treats schizophrenia and other psychotic disorders. The tablets and oral solution are also used for Tourette’s tics and for certain severe behavior problems in children. Your pr...
  • Tablets and oral solution are taken by mouth as your prescriber directs. Injections are given into a muscle by a healthcare provider, and Haldol Decanoate is given every 4 weeks. N...
  • Movement-related effects are the most common, such as stiffness, tremor, restlessness, or slowed movement. Headache and stomach pain can also happen. Tell us about any new movement...
  • Call for fever with severe stiffness and confusion, fainting or a racing or irregular heartbeat, seizures, or swelling and trouble breathing. These can be serious.
📖 Read our full Haloperidol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
27241-0264-01 27241-264-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE (27241-264-01) 2026-09-14 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Haloperidol .5 mg 69292-0580-01 Amici 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 59651-0789-01 Aurobindo 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 00832-1510-11 Upsher-Smith 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 11788-0071-01 AiPing 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 58657-0900-01 Method 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 70756-0001-11 Lifestar 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 51079-0733-20 Mylan 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 00378-0351-01 Mylan 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 58657-0700-01 Method 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 68382-0407-01 Zydus 100 tablets $0.086 AB Availability likely —
Haloperidol .5 mg 71247-0150-01 Innogenix, 100 tablets $0.112 AB FDA listed —
Haloperidol .5 mg 00904-7389-61 Major 100 tablets $0.113 AB Discontinued —
Haloperidol .5 mg 71335-2667-01 Bryant 100 tablets — AB FDA listed —
Haloperidol .5 mg 71335-2880-01 Bryant 100 tablets — AB FDA listed —
Haloperidol .5 mg 65841-0837-01 Zydus 100 tablets — AB FDA listed —
Haloperidol .5 mg 63629-9270-01 Bryant 100 tablets — AB FDA listed —
Haloperidol .5 mg 10135-0752-01 Marlex 100 tablets — AB FDA listed —
Haloperidol .5 mg 70518-2687-00 REMEDYREPACK 30 tablets — AB FDA listed —
Haloperidol .5 mg 72162-2621-01 Bryant 100 tablets — AB FDA listed —
Haloperidol .5 mg 72789-0566-01 PD-Rx 100 tablets — AB FDA listed —
Haloperidol .5 mg 48433-0151-20 Safecor 100 tablets — AB FDA listed —
Haloperidol .5 mg 72162-1683-01 Bryant 100 tablets — AB FDA listed —
Haloperidol .5 mg 82619-0105-01 Creekwood 100 tablets — AB FDA listed —
Haloperidol .5 mg 67046-1496-03 Coupler 30 tablets — AB FDA listed —
Haloperidol .5 mg 72205-0064-91 Novadoz 100 tablets — AB FDA listed —
Haloperidol .5 mgthis 27241-0264-01 Ajanta 100 tablets — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2026
On the market since
Sep 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAjanta Pharma USA Inc.
FDA applicationANDA218210 (ANDA)
Labeler code27241
First marketedSep 2026
Product typeHuman Prescription Drug
Portfolio174 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Haloperidol — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Haloperidol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$5.14M
Claims incl. refills
223.5K
Beneficiaries
82.3K
Spend / beneficiary
$62.40
Spend / claim
$22.99
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 27241-264-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 27241-0264-01, written without dashes as 27241026401. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 27241-0264-01, the first segment (27241) is the labeler code FDA assigned to Ajanta Pharma USA Inc.; the middle segment (0264) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Ajanta Pharma USA Inc.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Ajanta Pharma USA Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 27241-0256-11 · Ajanta 27241-0265-01 · Ajanta →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.